Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5624870 | 0.87 | ESR1 (0.58) | CYP19A1ESR1ESR2 | |
| SCHEMBL4639644 | 0.83 | LTA4H (0.45) | CYP19A1ESR1ESR2LTA4HTP53 | |
| SCHEMBL4639651 | 0.78 | ESR1 (0.42) | CYP19A1ESR1TP53 | |
| SCHEMBL6171429 | 0.77 | ESR1 (0.49) | CYP19A1ESR1ESR2SLC6A2SLC6A4 | |
| SCHEMBL4640168 | 0.75 | ESR1 (0.57) | CYP19A1ESR1ESR2 | |
| SCHEMBL5142315 | 0.75 | CYP19A1 (0.48) | CYP19A1ESR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4639647 | 0.73 | LTA4H (0.51) | ESR1ESR2LTA4HTP53 | |
| SCHEMBL4640645 | 0.71 | HSP90AA1 (0.39) | CYP19A1ESR1LTA4H | |
| SCHEMBL4641971 | 0.70 | ESR1 (0.59) | CYP19A1ESR1ESR2LTA4H | |
| SCHEMBL4639765 | 0.69 | ESR1 (0.44) | CYP19A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667999-A4 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7247646-B2 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1667999-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050137231-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-06-23 | — | — | US | disclosed |
| WO-2005028472-A1 | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137231-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR1, ESR2, ESRRG | CYP19A1 17/4885ESR1 1/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.